[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Jena\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100215602","pain-out-improvement-in-postoperative-pain-outcome-100215602",false,"NCT02083835","PAIN OUT: Improvement in Postoperative PAIN OUTcome","Improvement in Postoperative Pain Outcome","PAIN-OUT","Inclusion Criteria:\n\n* \\>= 18 years or \\>= 4 years for sub-project QUIPSI\u002FPAIN OUTinfant\n* patient is post-op day 1\n* patient is at least 6 hours on the ward\n* patient has given consent\n\nExclusion Criteria:\n\n* patient cannot communicate\n* patient is cognitively impaired\n* patient is asleep\n* patient is too ill\n* patient does not want to fill in the questionnaire","ALL","4 Years",{"count":20,"type":21},200000,"ESTIMATED","12 Months","OBSERVATIONAL","PAIN OUT is a multi-national, non-interventional registry and benchmark project, assessing and analysing clinical and patient-reported outcome data of postoperative pain.",[26],"Post-operative Pain",[28,29,30],"post-operative pain","paitent reported outcomes","quality improvement","RECRUITING","2026-04-30",{"date":34,"type":35},"2026-05-06","ACTUAL",{"date":37,"type":35},"2009-01",{"date":39,"type":21},"2030-12-31",{"name":41,"class":42},"University of Jena","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100431809","association-of-adjuvant-radiotherapy-of-non-metastatic-breast-carcinoma-with-immunomodulation-and-circulating-tumor-cell-phenotype-in-relation-to-patient-age-100431809","NCT04902937","Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.","CETC","Inclusion Criteria:\n\n* Primary diagnosis histologically confirmed invasive breast carcinoma pT1-4 pN0 or pN+ cM0\n* curative-intended breast-conserving therapy (BET) ± (neo-) adj. system therapy with subsequent adjuvant radiotherapy of the breast ± lymphatic drainage system planned\n* informed consent of the patient\n\nExclusion Criteria:\n\n* DCIS, Inflammatory breast carcinoma\n* Recurrence situation\n* Presence of distant metastases\n* Second malignancies \\\u003C 10 years prior to diagnosis of breast carcinoma\n* Prior exposure to radiotherapy","FEMALE","18 Years",{"count":54,"type":21},200,"In a prospective study, the influence of adjuvant radiotherapy in patients with non-metastatic breast carcinoma on the epithelial tumor cells (CETCs) circulating in the blood and their immunohistochemical characteristics depending on age will be investigated. In addition to a histopathological assignment of the CETCs as cells of the primary tumor, major trigger points of the immune system will be exploratively analyzed.\n\nFor this purpose, blood samples are taken from the patients at different time points after tumor resection and during adjuvant radiotherapy. In addition to the detection, isolation and genetic characterization of the CETCs, the determination of immunological biomarkers by immunophenotyping, among other methods, is planned. Furthermore, analyses of tissue from the primary tumor with respect to immunohistochemical features as well as tumor-infiltrating lymphocytes (TILs) are planned. The results will be classified and correlated especially with regard to patient age.\n\nAs there are insufficient data available for breast carcinoma regarding radiotherapeutic effects on the immune system depending on patient age, it is of great interest to better understand these molecular biological basics in order to identify potential prognostic biomarkers.",[57],"Tumor Cell, Circulating",[59,60,61,62,63],"Early Stage Breast cancer","Circulating Tumor Cells","Tumor-infiltrating lymphocytes","Radiotherapy","Immunophenotyping","2023-11-27",{"date":66,"type":35},"2023-11-28",{"date":68,"type":35},"2021-07-01",{"date":70,"type":21},"2026-12-31",{"name":41,"class":42},""]